

ImmuneID Raises \$50M Series A Financing

Client News

June 23, 2021

Gunderson Dettmer represented client ImmuneID, a precision immunology company, in its \$50 million Series A financing led by Alta Partners and included new investors Alexandria Venture Investments, Redwood Capital Investments, Section 32 and Tekla Capital Management, and existing investors including Arch Venture Partners, Longwood Fund, Pitango HealthTech, In-Q-Tel, Xfund and others.

In the [announcement of the transaction](#), CEO of ImmuneID David Donabedian, Ph.D. said, “This financing from an exceptional group of investors positions us to execute on our ambitious plans to develop a new generation of precision immunology therapeutics.”

The Gunderson deal team was led by Tim Ehrlich and included Georgios Pothoulakis and Jenna Mason.

Companies:

ImmuneID

Related People





Timothy H. Ehrlich
PARTNER
P +1 617 648 9399

Related Services

Early-Stage Company

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act